Safety and efficacy of DES in saphenous vein bypass graft PCI

Original title: Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: insights from the Veterans Affairs CART program. Reference: Aggarwal V et al. J Am Coll Cardiol. 2014;64:1825-1836.

 

This study retrospectively evaluated 2471 receiving after saphenous vein graft (SVG) PCI between October and September 2011. Outcomes were compared using propensity score matching between 895 patients treated with conventional bare metal stents (BMS) and 901 patients treated with drug eluting stents (DES).

The use of DES compared to BMS increased from 50% in 2008 to 69% in 2011. Peri procedural complications were low for both groups (2.8% with BMS vs 2.3% with DES; p=0 .54) but the long term showed differences.

At median follow up of 2.8 years, the use of DES was associated with lower mortality rates after propensity score matching (HR 0.72; CI 95% 0.57 to 0.89). Despite the difference in mortality, infarction rate was similar in both groups and these results were no different when looking at the different DES patients received. 

Conclusion

In this great cohort, increasing use of DES during SVG PCI was observed, compared to the use of BMS. Long term follow up showed DES were safe and effective. 

Editorial Comment

In the absence of a randomized study to confirm these data, the lower mortality rate observed with the use of DES in this study should be interpreted with caution, since it cannot be explained by a lower infarction rate.

Another limitation to this study is the lack of information on restenosis and revascularization, where we should see a greater advantage of DES.

SOLACI

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...